Eli Lilly's new shot shows solid weight loss in study — plus, a way for Nvidia to perk up
Airfind news item
By Paulina Likos
Published on March 19, 2026.
The CNBC Investing Club with Jim Cramer discusses the key moments of the day, including oil prices falling as Iran attacked a key LNG facility in Qatar, causing Brent international crude to briefly touch $119 per barrel. The S & P 500 also slipped below its 200-day moving average, a technical level that many long-term investors rely for for support. Cramer welcomed the fall in other commodities, including aluminum and steel, as rising raw material prices can lead to inflation and may make it difficult for the Federal Reserve to cut interest rates. Eli Lilly's new drug retatrutide in type 2 diabetes study showed superior weight loss compared to Mounjaro, with no plateau through 40 weeks. The company's new GLP-1 pill is expected to be approved by the FDA in early next month. Meanwhile, Cramer reiterated his "own, don't trade" stance on AI chip leader Nvidia, stating that the stock can rise if Sandisk "crosses over to the positive" if it improves. Other notable developments included a 1,200% rise in Sandisk's performance over the past year, Five Below, Nucor, Darden Restaurants, Align Technology, and Uber.
Read Original Article